MET-话题@MedSci

#MET#

1464篇内容 | 5827人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1896886, encodeId=d378189688683, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, objectTitle=临床预测模型的网状Meta分析, objectType=article, longId=216431, objectId=50a5216431af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50a5216431af, replyNumber=0, likeNumber=116, createdTime=2021-09-10, rootId=0, userName=一闲, userId=18fc139, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50a5216431af, moduleTitle=临床预测模型的网状Meta分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50a5216431af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1896784, encodeId=4ee31896e8425, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, objectTitle=Nat Metab：我国学者发现新冠病毒入侵的辅助受体, objectType=article, longId=203898, objectId=d39a203898c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d39a203898c2, replyNumber=0, likeNumber=111, createdTime=2021-01-09, rootId=0, userName=一闲, userId=18fc139, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d39a203898c2, moduleTitle=Nat Metab：我国学者发现新冠病毒入侵的辅助受体, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d39a203898c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1896917, encodeId=2805189691efc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, objectTitle=Front Oncol：复发鼻咽癌患者挽救手术治疗的疗效：meta分析, objectType=article, longId=218734, objectId=6c53218e3453, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c53218e3453, replyNumber=0, likeNumber=69, createdTime=2022-04-14, rootId=0, userName=一闲, userId=18fc139, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c53218e3453, moduleTitle=Front Oncol：复发鼻咽癌患者挽救手术治疗的疗效：meta分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c53218e3453)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1896794, encodeId=aa9f1896e94d2, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, objectTitle=Metab Eng：用西红柿治帕金森？英国科学家开发改良版西红柿，有望成为帕金森病药物来源, objectType=article, longId=204962, objectId=fc55204962f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc55204962f5, replyNumber=0, likeNumber=129, createdTime=2021-01-24, rootId=0, userName=一闲, userId=18fc139, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc55204962f5, moduleTitle=Metab Eng：用西红柿治帕金森？英国科学家开发改良版西红柿，有望成为帕金森病药物来源, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc55204962f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1896910, encodeId=36711896910d9, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, objectTitle=苏格兰药物联盟 (SMC) 批准Cabometyx/Opdivo组合治疗晚期肾癌患者, objectType=article, longId=218568, objectId=c15d218568ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c15d218568ba, replyNumber=0, likeNumber=113, createdTime=2022-03-10, rootId=0, userName=一闲, userId=18fc139, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c15d218568ba, moduleTitle=苏格兰药物联盟 (SMC) 批准Cabometyx/Opdivo组合治疗晚期肾癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c15d218568ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1896919, encodeId=3aab189691966, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, objectTitle=Nat Metab：吃得少可以延长寿命，但什么时候吃更重要, objectType=article, longId=218939, objectId=1184218939ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1184218939ca, replyNumber=0, likeNumber=114, createdTime=2022-09-05, rootId=0, userName=一闲, userId=18fc139, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1184218939ca, moduleTitle=Nat Metab：吃得少可以延长寿命，但什么时候吃更重要, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1184218939ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1896892, encodeId=4a081896892fd, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, objectTitle=Nutr Metab：改善乳腺癌幸存者身心健康和免疫状态组合利器：瑜伽+高剂量维D！, objectType=article, longId=217000, objectId=356221e00005, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=356221e00005, replyNumber=0, likeNumber=109, createdTime=2021-10-01, rootId=0, userName=一闲, userId=18fc139, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=356221e00005, moduleTitle=Nutr Metab：改善乳腺癌幸存者身心健康和免疫状态组合利器：瑜伽+高剂量维D！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=356221e00005)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1896776, encodeId=fcb81896e7612, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, objectTitle=Cell Metabolism: 重大进展！山东大学易凡团队鉴定了糖尿病性肾脏疾病的潜在治疗新靶点, objectType=article, longId=203456, objectId=2c04203456d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c04203456d5, replyNumber=0, likeNumber=102, createdTime=2021-01-10, rootId=0, userName=一闲, userId=18fc139, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c04203456d5, moduleTitle=Cell Metabolism: 重大进展！山东大学易凡团队鉴定了糖尿病性肾脏疾病的潜在治疗新靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c04203456d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1896902, encodeId=0a291896902d5, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, objectTitle=Diabetes Obes Metab：2型糖尿病患者索格列净疗效分析, objectType=article, longId=217855, objectId=913921e855ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=913921e855ab, replyNumber=0, likeNumber=87, createdTime=2021-12-23, rootId=0, userName=一闲, userId=18fc139, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=913921e855ab, moduleTitle=Diabetes Obes Metab：2型糖尿病患者索格列净疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=913921e855ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1896827, encodeId=d9d7189682e7f, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, objectTitle=Diabetes Obes Metab：双胰高血糖素样肽-1/胰高血糖素受体激动剂SAR425899可明显改善T2D患者的餐后糖代谢, objectType=article, longId=209702, objectId=ff5f209e02a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff5f209e02a5, replyNumber=0, likeNumber=102, createdTime=2021-12-14, rootId=0, userName=一闲, userId=18fc139, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff5f209e02a5, moduleTitle=Diabetes Obes Metab：双胰高血糖素样肽-1/胰高血糖素受体激动剂SAR425899可明显改善T2D患者的餐后糖代谢, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff5f209e02a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1896845, encodeId=16ae1896845bc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, objectTitle=每一篇meta分析都需要做阈值效应分析吗？, objectType=article, longId=211859, objectId=aab4211859f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aab4211859f5, replyNumber=0, likeNumber=87, createdTime=2021-08-15, rootId=0, userName=一闲, userId=18fc139, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aab4211859f5, moduleTitle=每一篇meta分析都需要做阈值效应分析吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aab4211859f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1896859, encodeId=37c31896859aa, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, objectTitle=Nat Commun：METTL3通过m6A修饰介导APC的表达促进肿瘤的发生发展, objectType=article, longId=213172, objectId=5dab2131e2a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5dab2131e2a5, replyNumber=0, likeNumber=103, createdTime=2022-04-23, rootId=0, userName=一闲, userId=18fc139, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5dab2131e2a5, moduleTitle=Nat Commun：METTL3通过m6A修饰介导APC的表达促进肿瘤的发生发展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5dab2131e2a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1896847, encodeId=e3d4189684e0e, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, objectTitle=Nature Metabolism：运动的好处因人而异，原来是血浆蛋白惹的祸！, objectType=article, longId=212038, objectId=d4c5212038a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4c5212038a9, replyNumber=0, likeNumber=80, createdTime=2021-08-16, rootId=0, userName=一闲, userId=18fc139, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4c5212038a9, moduleTitle=Nature Metabolism：运动的好处因人而异，原来是血浆蛋白惹的祸！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4c5212038a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1896858, encodeId=53c21896858a3, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, objectTitle=Lancet Respirat：Savolitinib在METex14跳跃变异阳性的中国肺癌患者中的疗效可期！, objectType=article, longId=213129, objectId=c62f21312916, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c62f21312916, replyNumber=0, likeNumber=126, createdTime=2022-01-19, rootId=0, userName=一闲, userId=18fc139, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c62f21312916, moduleTitle=Lancet Respirat：Savolitinib在METex14跳跃变异阳性的中国肺癌患者中的疗效可期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c62f21312916)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1896880, encodeId=b0ad1896880cc, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, objectTitle=Cell Metab：王红阳院士团队揭示NAD+代谢调节肿瘤免疫逃逸和增强PD-1/PD-L1治疗敏感性, objectType=article, longId=216078, objectId=9cf52160e830, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9cf52160e830, replyNumber=0, likeNumber=96, createdTime=2022-07-25, rootId=0, userName=一闲, userId=18fc139, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9cf52160e830, moduleTitle=Cell Metab：王红阳院士团队揭示NAD+代谢调节肿瘤免疫逃逸和增强PD-1/PD-L1治疗敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9cf52160e830)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1896860, encodeId=6350189686060, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, objectTitle=Clin Cancer Res: 考比替尼（cobimetinib）+ 维莫非尼（vemurafenib）对比安慰剂+ 维莫非尼（vemurafenib）治疗BRAF V600突变阳性转移性黑色素瘤的疗效和安全性: coBRIM研究5年长期随访结果, objectType=article, longId=213315, objectId=46ab21331526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46ab21331526, replyNumber=0, likeNumber=0, createdTime=2021-07-18, rootId=0, userName=一闲, userId=18fc139, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46ab21331526, moduleTitle=Clin Cancer Res: 考比替尼（cobimetinib）+ 维莫非尼（vemurafenib）对比安慰剂+ 维莫非尼（vemurafenib）治疗BRAF V600突变阳性转移性黑色素瘤的疗效和安全性: coBRIM研究5年长期随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46ab21331526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1896775, encodeId=58cd1896e75a6, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, objectTitle=Cell Metab ：邵志敏团队为三阴性乳腺癌“复旦分型”精准治疗策略再添新翼, objectType=article, longId=203440, objectId=ed4520344094, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed4520344094, replyNumber=0, likeNumber=157, createdTime=2021-09-09, rootId=0, userName=一闲, userId=18fc139, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed4520344094, moduleTitle=Cell Metab ：邵志敏团队为三阴性乳腺癌“复旦分型”精准治疗策略再添新翼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed4520344094)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1896890, encodeId=6f2c1896890fa, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, objectTitle=Clin Cancer Res：HDAC抑制剂Remetinostat凝胶用于基底细胞癌的治疗活性, objectType=article, longId=216890, objectId=3239216890aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3239216890aa, replyNumber=0, likeNumber=84, createdTime=2022-02-18, rootId=0, userName=一闲, userId=18fc139, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3239216890aa, moduleTitle=Clin Cancer Res：HDAC抑制剂Remetinostat凝胶用于基底细胞癌的治疗活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3239216890aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1896840, encodeId=01eb1896840ab, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, objectTitle=Liver Cancer：网状meta分析比较atezolizumab联合贝伐珠单抗对比其他治疗手段在不可切除肝细胞癌的疗效和安全性, objectType=article, longId=211519, objectId=7c45211519d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c45211519d9, replyNumber=0, likeNumber=144, createdTime=2022-04-08, rootId=0, userName=一闲, userId=18fc139, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c45211519d9, moduleTitle=Liver Cancer：网状meta分析比较atezolizumab联合贝伐珠单抗对比其他治疗手段在不可切除肝细胞癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c45211519d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1896896, encodeId=c4c7189689662, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, objectTitle=Front Oncol：吡咯替尼VS T-DM1用于转移性HER-2阳性经治乳腺癌患者的疗效和安全性：来自贝叶网状Meta分析, objectType=article, longId=217291, objectId=72b221e291fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72b221e291fa, replyNumber=0, likeNumber=71, createdTime=2022-03-26, rootId=0, userName=一闲, userId=18fc139, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72b221e291fa, moduleTitle=Front Oncol：吡咯替尼VS T-DM1用于转移性HER-2阳性经治乳腺癌患者的疗效和安全性：来自贝叶网状Meta分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72b221e291fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

MET

2020-05-29

一闲 (审核中...)

前往app查看评论内容

#MET#

临床预测模型的网状Meta分析

2021-09-10

一闲 (审核中...)

前往app查看评论内容

#MET#

Nat Metab：我国学者发现新冠病毒入侵的辅助受体

2021-01-09

一闲 (审核中...)

前往app查看评论内容

#MET#

Front Oncol：复发鼻咽癌患者挽救手术治疗的疗效：meta分析

2022-04-14

一闲 (审核中...)

前往app查看评论内容

#MET#

Metab Eng：用西红柿治帕金森？英国科学家开发改良版西红柿，有望成为帕金森病药物来源

2021-01-24

一闲 (审核中...)

前往app查看评论内容

#MET#

苏格兰药物联盟 (SMC) 批准Cabometyx/Opdivo组合治疗晚期肾癌患者

2022-03-10

一闲 (审核中...)

前往app查看评论内容

#MET#

Nat Metab：吃得少可以延长寿命，但什么时候吃更重要

2022-09-05

一闲 (审核中...)

前往app查看评论内容

#MET#

Nutr Metab：改善乳腺癌幸存者身心健康和免疫状态组合利器：瑜伽+高剂量维D！

2021-10-01

一闲 (审核中...)

前往app查看评论内容

#MET#

Cell Metabolism: 重大进展！山东大学易凡团队鉴定了糖尿病性肾脏疾病的潜在治疗新靶点

2021-01-10

一闲 (审核中...)

前往app查看评论内容

#MET#

Diabetes Obes Metab：2型糖尿病患者索格列净疗效分析

2021-12-23

一闲 (审核中...)

前往app查看评论内容

#MET#

Diabetes Obes Metab：双胰高血糖素样肽-1/胰高血糖素受体激动剂SAR425899可明显改善T2D患者的餐后糖代谢

2021-12-14

一闲 (审核中...)

前往app查看评论内容

#MET#

每一篇meta分析都需要做阈值效应分析吗？

2021-08-15

一闲 (审核中...)

前往app查看评论内容

#MET#

Nat Commun：METTL3通过m6A修饰介导APC的表达促进肿瘤的发生发展

2022-04-23

一闲 (审核中...)

前往app查看评论内容

#MET#

Nature Metabolism：运动的好处因人而异，原来是血浆蛋白惹的祸！

2021-08-16

一闲 (审核中...)

前往app查看评论内容

#MET#

Lancet Respirat：Savolitinib在METex14跳跃变异阳性的中国肺癌患者中的疗效可期！

2022-01-19

一闲 (审核中...)

前往app查看评论内容

#MET#

Cell Metab：王红阳院士团队揭示NAD+代谢调节肿瘤免疫逃逸和增强PD-1/PD-L1治疗敏感性

2022-07-25

一闲 (审核中...)

前往app查看评论内容

#MET#

Clin Cancer Res: 考比替尼（cobimetinib）+ 维莫非尼（vemurafenib）对比安慰剂+ 维莫非尼（vemurafenib）治疗BRAF V600突变阳性转移性黑色素瘤的疗效和安全性: coBRIM研究5年长期随访结果

2021-07-18

一闲 (审核中...)

前往app查看评论内容

#MET#

Cell Metab ：邵志敏团队为三阴性乳腺癌“复旦分型”精准治疗策略再添新翼

2021-09-09

一闲 (审核中...)

前往app查看评论内容

#MET#

Clin Cancer Res：HDAC抑制剂Remetinostat凝胶用于基底细胞癌的治疗活性

2022-02-18

一闲 (审核中...)

前往app查看评论内容

#MET#

Liver Cancer：网状meta分析比较atezolizumab联合贝伐珠单抗对比其他治疗手段在不可切除肝细胞癌的疗效和安全性

2022-04-08

一闲 (审核中...)

前往app查看评论内容

#MET#

Front Oncol：吡咯替尼VS T-DM1用于转移性HER-2阳性经治乳腺癌患者的疗效和安全性：来自贝叶网状Meta分析

2022-03-26

科室
- - 订阅+
  - 更多科室
工具
服务